Skip to main content
. Author manuscript; available in PMC: 2025 Jan 15.
Published in final edited form as: Clin Cancer Res. 2024 Jul 15;30(14):2865–2871. doi: 10.1158/1078-0432.CCR-24-0378

Table 1.

Characteristics of the efficacy population

Parameter N=97
Time since initial diagnosis (years)
Median 5.9
Min, max 1.6, 18.2
International Staging System (ISS) stage at study entry n (%)
 Stage I 61 (62.9)
 Stage II 22 (22.7)
 Stage III 14 (14.4)
Light chain type, n(%) at baseline(any)
Kappa light chain 15 (15.5)
Lambda light chain 9 (9.3%)
Biclonal 4 (4.1)
Immunoglobulin, n (%) At Baseline (Any)
Ig A 8 (8.2)
Ig G 57 (58.8)
Ig M 2 (2.1)
Ig D 2 (2.1)
Ig E 0
Not detected 0
Baseline cytogenetics risk n(%)
High risk 23 (23.7%)
Non-high risk 68 (70.1%)
Missing 6 (6.2%)
Presence of extramedullary plasmacytoma n (%)
 Yes 13 (13.4%)
 No 84 (86.6%)
Lytic bone disease n (%)
 Yes 69 (71.1)
 No 28 (28.9)
Tumor BCMA expression n (%)
<50% 5 (5)
≥50% 57 (59)
Unknown 35 (36.1%)
Number of prior antimyeloma regimens
Median (min, max) 6 (3, 18)
Distribution of prior antimyeloma regimens n (%)
   3 17 (17.5)
   4 16 (16.5)
   5 15 (15.5)
   >5 49 (50.5)
Prior stem cell transplant n (%)
 Yes 87 (89.7)
 1 prior transplant 70 (72.2)
>1 prior transplant 17 (17.5)
 No 10 (10.3)
Prior refractory status n (%)
Immunomodulatory Agent (IMiD) 97 (100)
Proteasome inhibitor (PI) 97 (100)
Anti-CD38 antibodies 97 (100)
Daratumumab 94 (96.9)
Double refractory (IMiD and PI) 97 (100)
Triple refractory (IMiD, PI and anti-CD38) 97 (100)
Penta-refractory 81 (83.5)
Prior refractory to last regimen, n (%) 97 (100)

Data from Source: BLA clinical review memorandum 125746/05